Novartis and BioAge partner on longevity, exercise targets
BioAge Labs, which began nearly a decade ago as an anti-aging biotech and then turned to obesity this year, is going back to its roots and teaming up with Novartis to find new drug targets ...
View ArticleRing Therapeutics cuts workforce in latest round of layoffs as CEO departs
Ring Therapeutics, a startup looking to advance a new type of virus to deliver gene therapies, has let go "just under 50%" of its workforce, a spokesperson told Endpoints News Wednesday morning. Ring...
View ArticleMerck’s long-awaited obesity move is an oral GLP-1 from China
Merck is finally making a move in obesity by licensing an oral GLP-1 candidate, though it's happening years after some of its big pharma peers. Like AstraZeneca did a year ago with ...
View ArticleTessera gets up to $50M from the Gates Foundation; Tvardi’s reverse merger
Plus, news about Sensorion, Soleno Therapeutics, Corvus and Hansa Biopharma: Tessera Therapeutics bags up to $50M for sickle cell disease R&D: The investment is part of Tessera’s new agreement with...
View ArticleBiosecure Act influence still felt even as China bill stalls
Last March, I received a flurry of texts and emails from readers. It was one of the strongest reactions I’ve ever gotten to an article. Endpoints News had just published my piece ...
View ArticleNovartis, AbbVie and PhRMA secure 340B court win in West Virginia
Novartis, AbbVie and industry group PhRMA on Tuesday notched a victory over a West Virginia law that would have required the companies to distribute drugs at reduced prices to an unlimited number of...
View ArticleUS drug spending surged to almost $450B in 2023
Popular weight loss and diabetes treatments contributed to a “faster overall growth” in prescription drug spending last year, according to a new report from the Centers for Medicare & Medicaid...
View ArticleDavid Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field
David Epstein has retired three times. And he quickly went to work when he got back in the saddle earlier this fall as CEO and chair of Ottimo Pharma, a preclinical biotech trying to take ...
View ArticleSangamo strikes brain-targeting AAV partnership with Astellas
Sangamo has made another gene therapy deal to keep the lights on for a few more months, extending its funding by another three months until at least mid-2025. On Thursday, the struggling California...
View ArticleRoche’s Parkinson’s drug flunks second mid-stage trial
Roche’s alpha-synuclein-targeting antibody has failed to slow the progression of motor symptoms in a mid-stage Parkinson’s disease test, marking the latest setback in a largely challenging year for the...
View ArticleEx-Color Health execs raise $10M to bring AI to pharma
Employees Nos. 1 and 2 of the $4.6 billion health tech startup Color Health have started their own company, aiming to tackle pharma's regulatory burden with generative AI. The San Francisco-based...
View ArticleVertex’s non-opioid pill disappoints in mid-stage chronic pain study
Vertex Pharmaceuticals announced highly anticipated results from a Phase 2 trial Thursday morning in a chronic pain condition, saying its non-opioid pain pill suzetrigine met the primary endpoint and...
View ArticleEndpoints winners and losers 2024: Best and worst biotech trends
Last year’s Endpoints News winners and losers list was such a hit that we decided to make it a tradition. As always, we’re keeping track of who’s ⬆️ and who’s ⬇️ in biopharma, the ideas ...
View ArticleHealth tech industry predicts cautious funding optimism in 2025
After a tough few years, healthcare startups are entering 2025 with cautious optimism. Twelve months ago, early-stage startups faced a funding cliff. Many didn’t survive: Across industries, more...
View ArticleSorriso claims a Phase 1b success for oral antibody in ulcerative colitis
A private startup from Salt Lake City aiming to develop oral antibodies says it has succeeded in an early trial, a potentially significant scientific advancement in a world where systemic treatments...
View ArticleBristol Myers pays $100M upfront to collaborate with Leqembi originator in...
Bristol Myers Squibb is partnering with the original developer of Leqembi in a new Alzheimer’s disease deal. The large drugmaker said Thursday that it's giving BioArctic $100 million upfront to license...
View ArticleLonza expands capsule footprint; BioCentriq's new HQ
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lonza is expanding its manufacturing sites in ...
View ArticleIn blow to compounders, FDA reaffirms tirzepatide shortage is over
The FDA has reaffirmed that the shortage of Eli Lilly’s blockbuster obesity and diabetes medications is resolved, dealing a blow to pharmacies and telehealth services that have capitalized on providing...
View ArticleGilead deepens its stake in Assembly Biosciences; NGM licenses out MASH drug
Plus, news about Abilita Therapeutics, Orion, Novartis, XGEN Venture, Palleon, Henlius, TigaTx, HERVolution Therapeutics and Krystal Biotech: Gilead now owns 30% of Assembly Biosciences: The drugmaker...
View ArticleWhat health tech startups can expect in 2025
This week, Shelby and I looked at the state of health tech funding as we head into next year. In our conversations with investors and bankers, we found some cautious ...
View Article